UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing…